摘要
目的探讨Her-2、EGR-1在正常卵巢、卵巢良性肿瘤以及卵巢恶性肿瘤组织中的的表达情况,分析Her-2、EGR-1与卵巢癌临床病例特点和预后的相关性。方法免疫组化法检测HER-2、EGR-1分别在A,B,C组的表达情况,统计分析其表达差异,分析HER-2、EGR-1与临床参数以及生存预后之间的关系。结果⑴HER-2的阳性率的表达与卵巢癌的FIGO分期、淋巴节是否转移有关(P<0.05),但是与年龄、病理类型、病理分级无关(P>0.05)。⑵EGR-1的表达率高低与卵巢癌FIGO分期、组织分化程度以及淋巴节结是否转移有关(P<0.05),但与年龄、病理类型无关(P>0.05)。⑶受访的卵巢癌患者5年总生存率是46.1%,中位生存时间是52.8个月。HER-2表达以及EGR-1表达的高低可能与预后相关。结论 HER-2、EGR-1在卵巢癌的发生发展中起重要作用,对判断卵巢癌的预后有一定的指导意义,HER-2、EGR-1有望作为肿瘤标志物、基因检测或治疗靶标。
Objective To investigate the expression of Her-2 and EGR-1 in normal ovarian tissue,ovarian benign tumor and ovarian malignant tumor,and to analyze the clinical characteristics of Her-2,EGR-1 and ovarian cancer.Correlation with prognosis.Methods Immunohistochemistry was used to detect the expression of HER-2 and EGR-1 in group A,B and C,and the differences in expression were analyzed statistically.The relationship between HER-2 and EGR-1 and clinical parameters and survival prognosis was analyzed.The expression of HER-2 positive rate was correlated with FIGO stage and lymph node metastasis of ovarian cancer(P<0.05),but not related to age,pathological type and pathological grade(P>0.05).The expression rate of EGR-1 was correlated with FIGO stage,tissue differentiation and lymph node dissection in ovarian cancer(P<0.05),but not related to age and pathological type(P>0.05).3.The 5-year overall survival rate of the patients with ovarian cancer was 46.1%,and the median survival time was 52.8 months.The expression of HER-2 and the level of EGR-1 expression may be associated with prognosis.Conclusion HER-2 and EGR-1 play an important role in the development of ovarian cancer,and have certain guiding significance for judging the prognosis of ovarian cancer.HER-2 and EGR-1 are expected to be tumor markers,gene detection or therapeutic targets.
作者
柯灿灿
缪振忠
王芬
KE Cancan;MIAO Zhenzhong;WANG Fen(Nanchang University,Nanchang,330006;Department of Obstetrics and Gynecology,The First Affiliated Hospital of Nanchang University,Nanchang,330006,China)
出处
《江西医药》
CAS
2018年第11期1219-1223,共5页
Jiangxi Medical Journal
基金
江西省卫生厅计生委2017年度科技计划项目
编号20175123
